Improving publication rates of biomarker results from cancer trials.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 23052254.
- Also identified by DOI 10.1158/1078-0432.CCR-12-2856.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mandatory nondiagnostic biopsies for biomarker research pose risk and inconvenience to patients with cancer that should be justified by the knowledge gained. This commentary reflects on the publication by Freeman and Kimmelman, which points to a potentially low publication rate of biomarker results from cancer clinical trials requiring nondiagnostic biopsies.
Medical subject headings
- Antineoplastic Agents
- Publications
- Research Report